查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2127946

抗體藥物複合體(ADC) 市場規模、佔有率、成長率、全球產業分析、區域趨勢以及 2026 年至 2034 年的預測。

Antibody Drug Conjugates Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 198 Pages | 商品交期: 2-3個工作天內

價格

抗體藥物複合體（ADC）市場的成長要素

2025年全球抗體藥物複合體（ADC）市場規模為186億美元，預計將從2026年的226億美元成長至2034年的680億美元，在預測期間（2026-2034年）複合年成長率高達14.76%。北美地區在2025年佔市場主導地位，市場佔有率達51.83%，這主要得益於先進癌症療法的高普及率、完善的醫療基礎設施以及新型ADC產品持續獲得監管部門的批准。

抗體藥物複合體（ADC）是一種標靶癌症療法，它將單株抗體與高效細胞毒性藥物結合。由於這些療法能夠選擇性地針對癌細胞，同時最大限度地減少對健康組織的損傷，因此是現代癌症治療的首選方案。癌症發病率的上升、對精準醫療需求的不斷成長、基於生物標記的診斷技術的普及以及連接子和有效載荷技術的持續進步，正在推動全球市場的擴張。

市場概覽

隨著製藥公司致力於開發下一代標靶治療，抗體藥物偶聯物（ADC）產業正經歷顯著成長。 ADC正擴大應用於乳癌、尿路上皮癌、淋巴瘤、肺癌、卵巢癌和胃癌的治療。連接子穩定性的提高、藥物與抗體比例的最佳化以及有效載荷技術的創新，正推動著治療效果的改善和治療應用範圍的擴展。

主要市場參與企業包括第一三共株式會社、Astra Zeneca、輝瑞公司、Astellas製藥公司、吉利德科學公司和羅氏公司，所有這些公司都在研發、收購和策略聯盟方面投入大量資金。

市場趨勢

下一代抗體偶聯藥物的研發

影響市場發展的關鍵趨勢之一是具有以下特徵的先進ADC平台的開發：

  • 位點特異性結合技術
  • 雙有效載荷ADC
  • 提高連接子穩定性
  • 提高腫瘤標靶化能力
  • 藥物抗體比的改善

這些創新正在擴大 ADC 的目標範圍，從 HER2 和 CD30 等傳統標靶擴展到 TROP2、CLDN6/9、CDH17 和 VEGF 等新標靶。

市場促進因素

標靶癌症療法的廣泛應用

醫療專業人員正逐漸從傳統化療轉向精準癌症治療。抗體藥物偶聯物（ADC）因其在提高療效的同時降低全身毒性，正成為患者和醫生都青睞的治療選擇。

生物標記檢測的日益普及使得針對 HER2、TROP2、Nectin-4、CD30 和葉酸受體 α 的 ADC 療法能夠更恰當地選擇患者，從而進一步促進市場成長。

市場限制因素

高昂的研發成本

開發ADC需要在以下領域進行大量投資：

  • 抗體設計
  • 連接子開發
  • 細胞毒性負荷的最佳化
  • 臨床試驗
  • 專業製造

生技研發的複雜性和成本可能成為小規模生技公司的障礙，並可能限制市場擴張。

市場機遇

增加對癌症藥物研發的投資

製藥公司和創業投資加強投資力度，為抗體偶聯藥物（ADC）市場創造了巨大的商機。各公司正在加速臨床試驗，探索新的癌症適應症，並拓展其下一代ADC的研發管線。

授權協議、合作關係和收購的數量正在增加，預計這將推動未來市場成長。

市場挑戰

專業製造能力有限

抗體藥物偶聯物（ADC）的生產需要高度專業化的設施，這些設施能夠在嚴格的密閉條件下處理強效細胞毒性化合物。此類設施數量有限，可能導致供應瓶頸和生產成本增加，對市場擴張構成挑戰。

細分分析

按產品/目標系列

至2025年，在Enhertu和Cadsila等產品的商業性成功推動下，靶向HER2的抗體偶聯藥物（ADC）細分市場佔主導地位。乳癌和胃癌的高接受度也持續支撐著該細分市場的成長。

針對葉酸受體α的ADC細分市場預計將經歷最快的成長，到2034年將以27.09%的複合年成長率成長。

依有效載荷類型

預計到 2025 年，微管抑制劑 ADC 細分市場將佔最大的市場佔有率，到 2026 年將佔市場佔有率的 36.3%。其主導地位得益於已通過核准的治療藥物，如 Adcetris、Padcev、 Kadcyla 、Polivy 和 Tivdak。

按疾病指徵

2025年，乳癌領域成為市場成長的主要驅動力，這主要得益於抗體偶聯藥物（ADC）在HER2陽性和HER2低表現乳癌治療的廣泛應用。預計到2026年，該領域將佔39.0%的市場佔有率。

透過行政途徑

靜脈注射領域佔市場主導地位，幾乎所有已通過核准的ADC療法都是透過靜脈輸注給藥，預計到2026年將佔總銷售額的99.7%。

最終用戶

2025 年，「醫院」細分市場將佔最大的市場佔有率，預計到 2026 年將保持 51.9% 的市場佔有率，這得益於其完善的腫瘤專科治療基礎設施和靜脈輸液設施。

區域分析

北美洲

預計到2025年，北美市場規模將達到96.4億美元，仍將是最大的區域市場。完善的保險報銷機制、高昂的癌症治療費用以及創新癌症療法的快速普及，都鞏固了該地區的主導地位。

美國

預計到 2026 年，美國 ADC 市場規模將達到 106.6 億美元，約佔全球銷售額的 47.2%。

歐洲

預計歐洲在預測期內將達到13.95%的複合年成長率。標靶治療的日益普及和有利的報銷機制將繼續支撐市場擴張。

預計到 2026 年，德國市場規模將達到 11.1 億美元，而英國市場預計將達到 6.9 億美元。

亞太地區

預計到 2026 年，亞太地區的癌症治療市場規模將達到 47.4 億美元，這主要得益於醫療保健支出增加、癌症發病率上升以及獲得先進癌症治療的機會改善。

預計到 2026 年，日本和中國的銷售額將分別達到約 15.4 億美元，而印度的銷售額預計將達到 2.5 億美元。

拉丁美洲、中東和非洲

先進的癌症治療方法正逐漸在這些地區普及。預計到2026年，拉丁美洲的癌症治療市場規模將達到8.7億美元，而海灣合作理事會（GCC）的市場規模預計將達到2.1億美元。

近期產業發展動態包括吉利德於 2026 年 4 月收購 Tubulis，禮來於 2026 年 4 月收購 CrossBridge Bio，以及Astra Zeneca在新加坡投資 15 億美元興建 ADC 生產設施。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
  • 市場趨勢

第4章：主要考慮因素

  • 抗體藥物複合體（ADC）的技術進步
  • 主要產業趨勢（合併、收購、合作等）
  • 新產品發布：按主要公司分類
  • 管道分析：按主要公司分類
  • 主要國家/地區的法規和還款狀況

第5章：2021-2034年全球抗體藥物複合體（ADC）市場分析、洞察與預測

  • 市場分析、洞察與預測：按產品/目標系列分類
    • 靶向HER2的ADC
    • 標靶nectin-4的抗體藥物偶聯物
    • 靶向 TROP2 的 ADC
    • 靶向CD30的抗體藥物偶聯物
    • 標靶CD79b的抗體藥物偶聯物
    • 靶向葉酸受體α的抗體藥物偶聯物
    • 其他
  • 市場分析、洞察與預測：按酬載等級分類
    • 拓樸異構酶I抑制劑抗體偶聯物
    • 微管抑制劑（ADCs）
    • 基於肌毒素類化合物的抗體藥物偶聯物
    • DNA損傷抗體藥物偶聯物
    • 其他
  • 市場分析、洞察與預測：按疾病適應症分類
    • 乳癌
    • 尿路上皮癌
    • 淋巴瘤
    • 肺癌
    • 卵巢癌
    • 胃癌和胃食道癌
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 靜脈
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院
    • 癌症專科醫療中心
    • 教學醫院及研究型醫院
    • 門診靜脈輸液治療中心
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美抗體藥物複合體（ADC）市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲抗體藥物複合體（ADC）市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區抗體藥物複合體（ADC）市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲抗體藥物複合體（ADC）市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲抗體藥物複合體（ADC）市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • DAIICHI SANKYO COMPANY, LIMITED
    • AstraZeneca
    • Pfizer Inc.
    • Gilead Sciences, Inc.
    • F. Hoffmann-La Roche Ltd
    • AbbVie Inc.
    • GSK plc
    • RemeGen
    • Astellas Pharma Inc.
    • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Product Code: FBI116146

Growth Factors of Antibody Drug Conjugates (ADC) Market

The global Antibody Drug Conjugates (ADC) market was valued at USD 18.60 billion in 2025 and is projected to grow from USD 22.60 billion in 2026 to USD 68.00 billion by 2034, registering a strong CAGR of 14.76% during the forecast period (2026-2034). North America dominated the market with a 51.83% share in 2025, supported by high adoption of advanced oncology therapies, strong healthcare infrastructure, and continuous regulatory approvals for novel ADC products.

Antibody Drug Conjugates are targeted cancer therapies that combine monoclonal antibodies with highly potent cytotoxic drugs. These therapies selectively target cancer cells while minimizing damage to healthy tissues, making them a preferred treatment option in modern oncology. Increasing prevalence of cancer, growing demand for precision medicine, rising biomarker-based diagnostics, and continuous advancements in linker and payload technologies are driving market expansion worldwide.

Market Overview

The ADC industry is witnessing remarkable growth as pharmaceutical companies focus on developing next-generation targeted therapies. ADCs are increasingly being used in breast cancer, urothelial cancer, lymphoma, lung cancer, ovarian cancer, and gastric cancer treatments. Enhanced linker stability, improved drug-to-antibody ratios, and innovative payload technologies are improving treatment outcomes and expanding therapeutic applications.

Major market participants include Daiichi Sankyo Company, AstraZeneca, Pfizer Inc., Astellas Pharma Inc., Gilead Sciences, Inc., and F. Hoffmann-La Roche Ltd., all of which are investing heavily in research, acquisitions, and strategic collaborations.

Market Trends

Development of Next-Generation ADCs

A significant trend shaping the market is the development of advanced ADC platforms featuring:

  • Site-specific conjugation technologies
  • Dual-payload ADCs
  • Improved linker stability
  • Enhanced tumor targeting capabilities
  • Higher drug-to-antibody ratios

These innovations are helping ADCs move beyond traditional targets such as HER2 and CD30 to emerging targets including TROP2, CLDN6/9, CDH17, and VEGF.

Market Drivers

Growing Adoption of Targeted Cancer Therapies

Healthcare providers are increasingly shifting from conventional chemotherapy toward precision oncology treatments. ADCs offer improved efficacy with reduced systemic toxicity, making them attractive treatment options for patients and physicians.

The growing use of biomarker testing allows better patient selection for ADC therapies targeting HER2, TROP2, Nectin-4, CD30, and Folate Receptor Alpha, further supporting market growth.

Market Restraints

High Research and Development Costs

ADC development requires significant investments in:

  • Antibody engineering
  • Linker development
  • Cytotoxic payload optimization
  • Clinical trials
  • Specialized manufacturing

The complexity and cost of development create barriers for smaller biotechnology companies and may limit market expansion.

Market Opportunities

Rising Investments in Oncology Drug Development

Growing investments from pharmaceutical companies and venture capital firms are creating major opportunities in the ADC market. Companies are accelerating clinical trials, exploring new cancer indications, and expanding next-generation ADC pipelines.

The increasing number of licensing agreements, partnerships, and acquisitions is expected to strengthen future market growth.

Market Challenges

Limited Specialized Manufacturing Capacity

ADC manufacturing requires highly specialized facilities capable of handling potent cytotoxic compounds under strict containment conditions. Limited availability of such facilities can create supply bottlenecks and increase production costs, posing a challenge to market expansion.

Segmentation Analysis

By Product/Target Family

The HER2-directed ADCs segment dominated the market in 2025 due to the commercial success of products such as Enhertu and Kadcyla. Strong adoption in breast and gastric cancers continues to support segment growth.

The Folate Receptor Alpha-directed ADCs segment is projected to witness the fastest growth, expanding at a CAGR of 27.09% through 2034.

By Payload Class

The Microtubule Inhibitor ADCs segment held the largest market share in 2025 and is expected to account for 36.3% of the market in 2026. Its dominance is supported by approved therapies such as Adcetris, Padcev, Kadcyla, Polivy, and Tivdak.

By Disease Indication

The Breast Cancer segment led the market in 2025 due to widespread use of ADCs in HER2-positive and HER2-low breast cancer treatment. The segment is expected to hold 39.0% market share in 2026.

By Route of Administration

The Intravenous segment dominated the market and is projected to account for 99.7% of total revenue in 2026, as nearly all approved ADC therapies are administered through IV infusion.

By End User

The Hospitals segment held the largest market share in 2025 and is expected to maintain 51.9% share in 2026 due to the availability of specialized oncology infrastructure and infusion facilities.

Regional Analysis

North America

North America remained the largest regional market with a value of USD 9.64 billion in 2025. Strong reimbursement systems, high cancer treatment expenditure, and rapid adoption of innovative oncology therapies support regional leadership.

United States

The U.S. ADC market is projected to reach USD 10.66 billion in 2026, accounting for approximately 47.2% of global revenue.

Europe

Europe is expected to register a CAGR of 13.95% during the forecast period. Growing use of targeted therapies and favorable reimbursement frameworks continue to support market expansion.

Germany is expected to reach USD 1.11 billion in 2026, while the U.K. market is projected at USD 0.69 billion.

Asia Pacific

Asia Pacific is anticipated to reach USD 4.74 billion in 2026, driven by increasing healthcare spending, rising cancer prevalence, and improved access to advanced oncology treatments.

Japan and China are each expected to generate approximately USD 1.54 billion in revenue in 2026, while India is projected to reach USD 0.25 billion.

Latin America and Middle East & Africa

These regions are witnessing gradual adoption of advanced cancer therapies. Latin America is expected to reach USD 0.87 billion in 2026, while the GCC market is projected at USD 0.21 billion.

Competitive Landscape

The antibody drug conjugates market is semi-consolidated, with major companies focusing on product approvals, pipeline expansion, acquisitions, and strategic collaborations.

Leading companies include:

  • Daiichi Sankyo Company, Limited
  • AstraZeneca
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • GSK plc
  • RemeGen
  • Astellas Pharma Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Recent industry developments include Gilead's acquisition of Tubulis in April 2026, Eli Lilly's acquisition of CrossBridge Bio in April 2026, and AstraZeneca's USD 1.5 billion ADC manufacturing facility investment in Singapore.

Conclusion

The global antibody drug conjugates market is entering a period of rapid expansion driven by increasing adoption of precision oncology, rising cancer prevalence, and continuous innovation in ADC technology. Valued at USD 18.60 billion in 2025, the market is expected to grow to USD 22.60 billion in 2026 and reach USD 68.00 billion by 2034. Advances in next-generation ADC platforms, growing investments in oncology drug development, expanding treatment indications, and increasing regulatory approvals will continue to create substantial growth opportunities for market participants throughout the forecast period.

Segmentation By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Region

By Product/Target Family * HER2-directed ADCs

  • Nectin-4-directed ADCs
  • TROP2-directed ADCs
  • CD30-directed ADCs
  • CD79b-directed ADCs
  • Folate Receptor Alpha-directed ADCs
  • Others

By Payload Class * Topoisomerase I Inhibitor ADCs

  • Microtubule Inhibitor ADCs
  • Maytansinoid ADCs
  • DNA-damaging ADCs
  • Others

By Disease Indication * Breast Cancer

  • Urothelial Cancer
  • Lymphoma
  • Lung Cancer
  • Ovarian Cancer
  • Gastric & Gastroesophageal Cancer
  • Others

By Route of Administration * Intravenous

  • Others

By End User * Hospitals

  • Cancer Specialty Centers
  • Academic & Research Hospitals
  • Ambulatory Infusion Centers
  • Others

By Region * North America (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country)

    • U.S.
    • Canada
  • Europe (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Challenges
  • 3.5. Market Trends

4. Key Insights

  • 4.1. Technological Advancements in Antibody Drug Conjugates
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. New Product Launches, By Key Players
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Regulatory & Reimbursement Scenario, By Key Countries/Region

5. Global Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product/Target Family
    • 5.1.1. HER2-directed ADCs
    • 5.1.2. Nectin-4-directed ADCs
    • 5.1.3. TROP2-directed ADCs
    • 5.1.4. CD30-directed ADCs
    • 5.1.5. CD79b-directed ADCs
    • 5.1.6. Folate Receptor Alpha-directed ADCs
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Payload Class
    • 5.2.1. Topoisomerase I Inhibitor ADCs
    • 5.2.2. Microtubule Inhibitor ADCs
    • 5.2.3. Maytansinoid ADCs
    • 5.2.4. DNA-damaging ADCs
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.3.1. Breast Cancer
    • 5.3.2. Urothelial Cancer
    • 5.3.3. Lymphoma
    • 5.3.4. Lung Cancer
    • 5.3.5. Ovarian Cancer
    • 5.3.6. Gastric & Gastroesophageal Cancer
    • 5.3.7. Others
  • 5.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.4.1. Intravenous
    • 5.4.2. Others
  • 5.5. Market Analysis, Insights and Forecast - By End User
    • 5.5.1. Hospitals
    • 5.5.2. Cancer Specialty Centers
    • 5.5.3. Academic & Research Hospitals
    • 5.5.4. Ambulatory Infusion Centers
    • 5.5.5. Others
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product/Target Family
    • 6.1.1. HER2-directed ADCs
    • 6.1.2. Nectin-4-directed ADCs
    • 6.1.3. TROP2-directed ADCs
    • 6.1.4. CD30-directed ADCs
    • 6.1.5. CD79b-directed ADCs
    • 6.1.6. Folate Receptor Alpha-directed ADCs
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Payload Class
    • 6.2.1. Topoisomerase I Inhibitor ADCs
    • 6.2.2. Microtubule Inhibitor ADCs
    • 6.2.3. Maytansinoid ADCs
    • 6.2.4. DNA-damaging ADCs
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.3.1. Breast Cancer
    • 6.3.2. Urothelial Cancer
    • 6.3.3. Lymphoma
    • 6.3.4. Lung Cancer
    • 6.3.5. Ovarian Cancer
    • 6.3.6. Gastric & Gastroesophageal Cancer
    • 6.3.7. Others
  • 6.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.4.1. Intravenous
    • 6.4.2. Others
  • 6.5. Market Analysis, Insights and Forecast - By End User
    • 6.5.1. Hospitals
    • 6.5.2. Cancer Specialty Centers
    • 6.5.3. Academic & Research Hospitals
    • 6.5.4. Ambulatory Infusion Centers
    • 6.5.5. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product/Target Family
    • 7.1.1. HER2-directed ADCs
    • 7.1.2. Nectin-4-directed ADCs
    • 7.1.3. TROP2-directed ADCs
    • 7.1.4. CD30-directed ADCs
    • 7.1.5. CD79b-directed ADCs
    • 7.1.6. Folate Receptor Alpha-directed ADCs
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Payload Class
    • 7.2.1. Topoisomerase I Inhibitor ADCs
    • 7.2.2. Microtubule Inhibitor ADCs
    • 7.2.3. Maytansinoid ADCs
    • 7.2.4. DNA-damaging ADCs
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.3.1. Breast Cancer
    • 7.3.2. Urothelial Cancer
    • 7.3.3. Lymphoma
    • 7.3.4. Lung Cancer
    • 7.3.5. Ovarian Cancer
    • 7.3.6. Gastric & Gastroesophageal Cancer
    • 7.3.7. Others
  • 7.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.4.1. Intravenous
    • 7.4.2. Others
  • 7.5. Market Analysis, Insights and Forecast - By End User
    • 7.5.1. Hospitals
    • 7.5.2. Cancer Specialty Centers
    • 7.5.3. Academic & Research Hospitals
    • 7.5.4. Ambulatory Infusion Centers
    • 7.5.5. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product/Target Family
    • 8.1.1. HER2-directed ADCs
    • 8.1.2. Nectin-4-directed ADCs
    • 8.1.3. TROP2-directed ADCs
    • 8.1.4. CD30-directed ADCs
    • 8.1.5. CD79b-directed ADCs
    • 8.1.6. Folate Receptor Alpha-directed ADCs
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Payload Class
    • 8.2.1. Topoisomerase I Inhibitor ADCs
    • 8.2.2. Microtubule Inhibitor ADCs
    • 8.2.3. Maytansinoid ADCs
    • 8.2.4. DNA-damaging ADCs
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.3.1. Breast Cancer
    • 8.3.2. Urothelial Cancer
    • 8.3.3. Lymphoma
    • 8.3.4. Lung Cancer
    • 8.3.5. Ovarian Cancer
    • 8.3.6. Gastric & Gastroesophageal Cancer
    • 8.3.7. Others
  • 8.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.4.1. Intravenous
    • 8.4.2. Others
  • 8.5. Market Analysis, Insights and Forecast - By End User
    • 8.5.1. Hospitals
    • 8.5.2. Cancer Specialty Centers
    • 8.5.3. Academic & Research Hospitals
    • 8.5.4. Ambulatory Infusion Centers
    • 8.5.5. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product/Target Family
    • 9.1.1. HER2-directed ADCs
    • 9.1.2. Nectin-4-directed ADCs
    • 9.1.3. TROP2-directed ADCs
    • 9.1.4. CD30-directed ADCs
    • 9.1.5. CD79b-directed ADCs
    • 9.1.6. Folate Receptor Alpha-directed ADCs
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Payload Class
    • 9.2.1. Topoisomerase I Inhibitor ADCs
    • 9.2.2. Microtubule Inhibitor ADCs
    • 9.2.3. Maytansinoid ADCs
    • 9.2.4. DNA-damaging ADCs
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.3.1. Breast Cancer
    • 9.3.2. Urothelial Cancer
    • 9.3.3. Lymphoma
    • 9.3.4. Lung Cancer
    • 9.3.5. Ovarian Cancer
    • 9.3.6. Gastric & Gastroesophageal Cancer
    • 9.3.7. Others
  • 9.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.4.1. Intravenous
    • 9.4.2. Others
  • 9.5. Market Analysis, Insights and Forecast - By End User
    • 9.5.1. Hospitals
    • 9.5.2. Cancer Specialty Centers
    • 9.5.3. Academic & Research Hospitals
    • 9.5.4. Ambulatory Infusion Centers
    • 9.5.5. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product/Target Family
    • 10.1.1. HER2-directed ADCs
    • 10.1.2. Nectin-4-directed ADCs
    • 10.1.3. TROP2-directed ADCs
    • 10.1.4. CD30-directed ADCs
    • 10.1.5. CD79b-directed ADCs
    • 10.1.6. Folate Receptor Alpha-directed ADCs
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Payload Class
    • 10.2.1. Topoisomerase I Inhibitor ADCs
    • 10.2.2. Microtubule Inhibitor ADCs
    • 10.2.3. Maytansinoid ADCs
    • 10.2.4. DNA-damaging ADCs
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.3.1. Breast Cancer
    • 10.3.2. Urothelial Cancer
    • 10.3.3. Lymphoma
    • 10.3.4. Lung Cancer
    • 10.3.5. Ovarian Cancer
    • 10.3.6. Gastric & Gastroesophageal Cancer
    • 10.3.7. Others
  • 10.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.4.1. Intravenous
    • 10.4.2. Others
  • 10.5. Market Analysis, Insights and Forecast - By End User
    • 10.5.1. Hospitals
    • 10.5.2. Cancer Specialty Centers
    • 10.5.3. Academic & Research Hospitals
    • 10.5.4. Ambulatory Infusion Centers
    • 10.5.5. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. DAIICHI SANKYO COMPANY, LIMITED
    • 11.2.2. AstraZeneca
    • 11.2.3. Pfizer Inc.
    • 11.2.4. Gilead Sciences, Inc.
    • 11.2.5. F. Hoffmann-La Roche Ltd
    • 11.2.6. AbbVie Inc.
    • 11.2.7. GSK plc
    • 11.2.8. RemeGen
    • 11.2.9. Astellas Pharma Inc.
    • 11.2.10. Jiangsu Hengrui Pharmaceuticals Co., Ltd.

List of Tables

  • Table 1: Global Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Product/Target Family, 2021-2034
  • Table 2: Global Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Payload Class, 2021-2034
  • Table 3: Global Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 4: Global Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 5: Global Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 6: Global Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 7: North America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Product/Target Family, 2021-2034
  • Table 8: North America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Payload Class, 2021-2034
  • Table 9: North America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 10: North America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 11: North America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 12: North America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 13: Europe Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Product/Target Family, 2021-2034
  • Table 14: Europe Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Payload Class, 2021-2034
  • Table 15: Europe Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 16: Europe Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 17: Europe Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 18: Europe Antibody Drug Conjugates Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Product/Target Family, 2021-2034
  • Table 20: Asia Pacific Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Payload Class, 2021-2034
  • Table 21: Asia Pacific Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 22: Asia Pacific Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 23: Asia Pacific Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 24: Asia Pacific Antibody Drug Conjugates Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 25: Latin America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Product/Target Family, 2021-2034
  • Table 26: Latin America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Payload Class, 2021-2034
  • Table 27: Latin America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 28: Latin America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 29: Latin America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 30: Latin America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Product/Target Family, 2021-2034
  • Table 32: Middle East & Africa Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Payload Class, 2021-2034
  • Table 33: Middle East & Africa Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 34: Middle East & Africa Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 35: Middle East & Africa Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 36: Middle East & Africa Antibody Drug Conjugates Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Antibody Drug Conjugates Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034
  • Figure 2: Global Antibody Drug Conjugates Market Value Share (%), By Product/Target Family, 2025 & 2034
  • Figure 3: Global Antibody Drug Conjugates Market Value Share (%), By Payload Class, 2025 & 2034
  • Figure 4: Global Antibody Drug Conjugates Market Value Share (%), By Disease Indication, 2025 & 2034
  • Figure 5: Global Antibody Drug Conjugates Market Value Share (%), By Route of Administration, 2025 & 2034
  • Figure 6: Global Antibody Drug Conjugates Market Value Share (%), By End User, 2025 & 2034
  • Figure 7: Global Antibody Drug Conjugates Market Value Share (%), By Region, 2025 & 2034
  • Figure 8: North America Antibody Drug Conjugates Market Value (USD billion), By Product/Target Family, 2025 & 2034
  • Figure 9: North America Antibody Drug Conjugates Market Value Share (%), By Product/Target Family, 2025
  • Figure 10: North America Antibody Drug Conjugates Market Value (USD billion), By Payload Class, 2025 & 2034
  • Figure 11: North America Antibody Drug Conjugates Market Value Share (%), By Payload Class, 2025
  • Figure 12: North America Antibody Drug Conjugates Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 13: North America Antibody Drug Conjugates Market Value Share (%), By Disease Indication, 2025
  • Figure 14: North America Antibody Drug Conjugates Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 15: North America Antibody Drug Conjugates Market Value Share (%), By Route of Administration, 2025
  • Figure 16: North America Antibody Drug Conjugates Market Value (USD billion), By End User, 2025 & 2034
  • Figure 17: North America Antibody Drug Conjugates Market Value Share (%), By End User, 2025
  • Figure 18: North America Antibody Drug Conjugates Market Value (USD billion), by Country, 2025 & 2034
  • Figure 19: North America Antibody Drug Conjugates Market Value Share (%), by Country, 2025
  • Figure 20: Europe Antibody Drug Conjugates Market Value (USD billion), By Product/Target Family, 2025 & 2034
  • Figure 21: Europe Antibody Drug Conjugates Market Value Share (%), By Product/Target Family, 2025
  • Figure 22: Europe Antibody Drug Conjugates Market Value (USD billion), By Payload Class, 2025 & 2034
  • Figure 23: Europe Antibody Drug Conjugates Market Value Share (%), By Payload Class, 2025
  • Figure 24: Europe Antibody Drug Conjugates Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 25: Europe Antibody Drug Conjugates Market Value Share (%), By Disease Indication, 2025
  • Figure 26: Europe Antibody Drug Conjugates Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 27: Europe Antibody Drug Conjugates Market Value Share (%), By Route of Administration, 2025
  • Figure 28: Europe Antibody Drug Conjugates Market Value (USD billion), By End User, 2025 & 2034
  • Figure 29: Europe Antibody Drug Conjugates Market Value Share (%), By End User, 2025
  • Figure 30: Europe Antibody Drug Conjugates Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Antibody Drug Conjugates Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Antibody Drug Conjugates Market Value (USD billion), By Product/Target Family, 2025 & 2034
  • Figure 33: Asia Pacific Antibody Drug Conjugates Market Value Share (%), By Product/Target Family, 2025
  • Figure 34: Asia Pacific Antibody Drug Conjugates Market Value (USD billion), By Payload Class, 2025 & 2034
  • Figure 35: Asia Pacific Antibody Drug Conjugates Market Value Share (%), By Payload Class, 2025
  • Figure 36: Asia Pacific Antibody Drug Conjugates Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 37: Asia Pacific Antibody Drug Conjugates Market Value Share (%), By Disease Indication, 2025
  • Figure 38: Asia Pacific Antibody Drug Conjugates Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 39: Asia Pacific Antibody Drug Conjugates Market Value Share (%), By Route of Administration, 2025
  • Figure 40: Asia Pacific Antibody Drug Conjugates Market Value (USD billion), By End User, 2025 & 2034
  • Figure 41: Asia Pacific Antibody Drug Conjugates Market Value Share (%), By End User, 2025
  • Figure 42: Asia Pacific Antibody Drug Conjugates Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Antibody Drug Conjugates Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 44: Latin America Antibody Drug Conjugates Market Value (USD billion), By Product/Target Family, 2025 & 2034
  • Figure 45: Latin America Antibody Drug Conjugates Market Value Share (%), By Product/Target Family, 2025
  • Figure 46: Latin America Antibody Drug Conjugates Market Value (USD billion), By Payload Class, 2025 & 2034
  • Figure 47: Latin America Antibody Drug Conjugates Market Value Share (%), By Payload Class, 2025
  • Figure 48: Latin America Antibody Drug Conjugates Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 49: Latin America Antibody Drug Conjugates Market Value Share (%), By Disease Indication, 2025
  • Figure 50: Latin America Antibody Drug Conjugates Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 51: Latin America Antibody Drug Conjugates Market Value Share (%), By Route of Administration, 2025
  • Figure 52: Latin America Antibody Drug Conjugates Market Value (USD billion), By End User, 2025 & 2034
  • Figure 53: Latin America Antibody Drug Conjugates Market Value Share (%), By End User, 2025
  • Figure 54: Latin America Antibody Drug Conjugates Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Antibody Drug Conjugates Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Antibody Drug Conjugates Market Value (USD billion), By Product/Target Family, 2025 & 2034
  • Figure 57: Middle East & Africa Antibody Drug Conjugates Market Value Share (%), By Product/Target Family, 2025
  • Figure 58: Middle East & Africa Antibody Drug Conjugates Market Value (USD billion), By Payload Class, 2025 & 2034
  • Figure 59: Middle East & Africa Antibody Drug Conjugates Market Value Share (%), By Payload Class, 2025
  • Figure 60: Middle East & Africa Antibody Drug Conjugates Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 61: Middle East & Africa Antibody Drug Conjugates Market Value Share (%), By Disease Indication, 2025
  • Figure 62: Middle East & Africa Antibody Drug Conjugates Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 63: Middle East & Africa Antibody Drug Conjugates Market Value Share (%), By Route of Administration, 2025
  • Figure 64: Middle East & Africa Antibody Drug Conjugates Market Value (USD billion), By End User, 2025 & 2034
  • Figure 65: Middle East & Africa Antibody Drug Conjugates Market Value Share (%), By End User, 2025
  • Figure 66: Middle East & Africa Antibody Drug Conjugates Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Antibody Drug Conjugates Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 68: Global Antibody Drug Conjugates Market Share (%), by Company, 2025